Cidara Therapeutics, Inc. (CDTX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CDTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CDTX Revenue Analysis (2013–2024)
As of March 1, 2026, Cidara Therapeutics, Inc. (CDTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, CDTX's 5-year compound annual growth rate (CAGR) stands at -42.9%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $64.4 million in 2022.
Revenue diversification analysis shows CDTX's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and SCNI (+303.9% YoY). Compare CDTX vs BNTX →
Peer Comparison
Compare CDTX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CDTXCurrent | $0 | - | -42.9% | -13811.9% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% | |
| VIR | $69M | -7.6% | +0.4% | -682.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.3M | -94.5% | $1.3M | 100.0% | $-176,102,000 | -13811.9% |
| 2023 | $23.3M | -63.9% | $-13,480,000 | -57.9% | $-27,060,000 | -116.2% |
| 2022 | $64.4M | +30.0% | $64.4M | 100.0% | $-33,503,000 | -52.0% |
| 2021 | $49.6M | +310.8% | $-23,515,000 | -47.4% | $-42,255,000 | -85.2% |
| 2020 | $12.1M | -42.3% | $12.1M | 100.0% | $-71,849,000 | -595.4% |
| 2019 | $20.9M | - | $-25,486,000 | -121.9% | $-41,724,000 | -199.5% |
| 2018 | $0 | - | $-523,000 | - | $-63,285,000 | - |
| 2017 | $0 | - | $-667,000 | - | $-55,721,000 | - |
| 2016 | $0 | - | $-732,000 | - | $-48,436,000 | - |
| 2015 | $0 | - | $-461,000 | - | $-32,313,000 | - |
See CDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CDTX vs AGIO
See how CDTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CDTX's revenue growth accelerating or slowing?
CDTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: -42.9%.
What is CDTX's long-term revenue growth rate?
Cidara Therapeutics, Inc.'s 5-year revenue CAGR of -42.9% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CDTX's revenue distributed by segment?
CDTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.